


Developing first-in-class, novel mechanism of action, non-opiate drugs specifically for the non-addictive treatment of neuropathic pain

Chronic & Neuropathic Pain Unmet Need

- Over 116 million US adults have chronic pain; over 20 million of those suffer from neuropathic pain
- Chemotherapy, diabetic, and post-surgical are the most common causes
- Neuropathic pain greatly impairs an individual's quality of life and there are currently NO effective treatments
- Neuropathic pain market is estimated to grow to \$13.3 billion with a 6.2% CAGR by 2030¹

1. Coherent Market Insights, 2025

Global Neuropathic Pain Market



2. Precedence Research, Dec 2024 (Forecast Period 2024-2034)

Limited, Ineffective Therapeutic Options


- Current treatment options for neuropathic pain include anticonvulsants, antidepressants, steroids and opioids
- Opioids are one of the most common treatments for neuropathic pain despite lack of efficacy, leading to potential misuse and addiction (~30%)
- Researchers have found limited efficacy with gabapentinoids for neuropathic pain despite widespread use (gabapentin: >\$1.5B global market, Lyrica®: >\$3.6B at peak) for neuropathic pain despite widespread use (*Goodman & Brett JAMA Intern Med 2019*)
- Duloxetine (Cymbalta®; Lilly) resulted in minimal pain reduction in patients with CIPN (Smith et al. JAMA 2013)

Chemotherapy Induced Peripheral Neuropathy (CIPN)

- CIPN is a progressive, enduring, and often irreversible condition featuring pain, numbness, tingling and sensitivity to cold in the hands and feet (sometimes progressing to the arms and legs)
- 30% of all patients receiving chemotherapy and 93% of those receiving platins develop CIPN (*Wolf et al. Eur J Cancer 2008; Hall et al. BMC Fam Pract 2008; Freynhagen & Bennett, Brit Med J 2009; von Hehn et al., Neuron 2012; Colvin Pain 2019*)
- Patients often deem CIPN to be so unbearable that they are willing to discontinue treatment despite the potential for a decrease in survival


Akelos – Selective HCN1 Blocker

HCN1 Expression Drives CIPN



- HCN1 channel expression and function upregulated in CIPN, peripheral nerve injury and diabetic neuropathy
- Oxaliplatin increased HCN1 mRNA expression, driving chemotherapy-induced hypersensitivity

HCN Blocker Relieves Pain



Akelos' Novel Mechanism of Action

- When sensory neurons are injured, HCN1 activity is enhanced
- Akelos has identified a molecule nearly identical in structure to a known, safe existing anesthetic, but optimized to selectively and potently inhibit the HCN1 channel and limit the experience of pain
- Analgesia without anesthesia

Reducing Neuron "Excitability"



Proprietary Assets Targeting HCN1 Pathways

- Pre-clinical studies show Akelos' compound is safe in animal studies (no motor or cardiovascular side-effects, no abuse potential)
- Efficacy was statistically significant as measured by reductions in the time and probability of animal subject response to mechanical and thermal stimulation following nerve injury
- Akelos' "**anchor-tether**" strategy optimizes access of the pharmacophore region of its binding site, thus achieving high effector-site concentration
- 2nd generation use of HCN1-selective antibody as anchor further enhances tissue targeting
- Latest Development and IND Enablement evaluation data indicates that AKE-1018 and the chemical series possess favorable drug-like properties

Akelos – Experienced Team and Track Record of Success

Intellectual Property

- Patents claiming Akelos' lead compound AKL1018 and methods of treating pain with this compound have issued or are allowed in the US, China, Japan and Australia and expected to issue in Europe and Canada
- All derive from PCT International Patent Application, PCT/US2019/039493, "Substituted Alkylphenols as HCN1 Antagonists"

Company Milestones

- Exclusive license to IP and collaborative partnership with Cornell to develop HCN1 selective compounds
- Lead compounds demonstrate efficacy and safety in extensive pre-clinical testing
- \$11.7 million non-dilutive funding in the technology to date including:
 - \$3.67 million fast-track grant from the National Institute of Neurological Disorders and Stroke

First Class Team, First-in-Class Solution for Neuropathic Pain

- Innovative, biopharmaceutical company **founded to address the unmet need of patients suffering from debilitating neuropathic pain**
- Akelos is led by a world-renowned leadership team and scientific advisory board composed of Nobel prize recipients, leading clinical anesthesiologists specializing in pain management, the former Chief Counsel for the FDA, a former US Senator and senior pharmaceutical executives with experience developing pain drugs

The Opportunity

- Akelos is seeking a \$14 million dollar investment to:
- Fund pre-clinical drug development and IND enabling studies for their lead programs
- Build out R&D and regulatory teams in anticipation of Ph1 trials

To Express Interest, Contact:

Dr. Steven R. Fox
President and Chief Executive Officer
drstevefox@akelosinc.com
(212) 953-1544

215 East 68th Street, Suite 26B
New York, NY 10065